Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hologic Women’s Health Biz Wows Investors As Stock Soars 45% In 2007

This article was originally published in The Gray Sheet

Executive Summary

Hologic is looking this year to build on its status as the largest company dedicated to women's health care by launching a three-dimensional digital mammography system capable of significantly improved performance over 2D systems

You may also be interested in...



RSNA 2008 Annual Meeting In Brief

Hologic's tomosynthesis: New data presented at Radiological Society of North America conference in Chicago on Dec. 2 shows Hologics' tomosynthesis breast mammography system Selenia Dimensions has a lower recall rate than traditional mammography and can detect tumors in dense breasts. The Selenia Dimensions takes a series of images to show tissue structure in three dimensions, allowing physicians to see an anomaly in breast tissue from multiple angles. Hologic originally expected FDA to approve the PMA for Selenia Dimensions in the second quarter of 2008, but FDA approval for the device was pushed back by a July 30 letter from the agency, requesting additional information (1"The Gray Sheet" Jan. 21, 2008, p. 7). FDA will likely convene an advisory panel meeting to review the PMA. Selenia Dimensions received a CE mark in Europe during the firm's fourth fiscal quarter of 2008. "We continue to see approval as when, not if," Morgan Stanley analyst David Lewis writes in a Dec. 4 report on tomosynthesis. "Focus will eventually turn to the technology, which has garnered considerable physician interest as a revolution versus digital, although concerns on adoption, workflow and applicable market exist.

RSNA 2008 Annual Meeting In Brief

Hologic's tomosynthesis: New data presented at Radiological Society of North America conference in Chicago on Dec. 2 shows Hologics' tomosynthesis breast mammography system Selenia Dimensions has a lower recall rate than traditional mammography and can detect tumors in dense breasts. The Selenia Dimensions takes a series of images to show tissue structure in three dimensions, allowing physicians to see an anomaly in breast tissue from multiple angles. Hologic originally expected FDA to approve the PMA for Selenia Dimensions in the second quarter of 2008, but FDA approval for the device was pushed back by a July 30 letter from the agency, requesting additional information (1"The Gray Sheet" Jan. 21, 2008, p. 7). FDA will likely convene an advisory panel meeting to review the PMA. Selenia Dimensions received a CE mark in Europe during the firm's fourth fiscal quarter of 2008. "We continue to see approval as when, not if," Morgan Stanley analyst David Lewis writes in a Dec. 4 report on tomosynthesis. "Focus will eventually turn to the technology, which has garnered considerable physician interest as a revolution versus digital, although concerns on adoption, workflow and applicable market exist.

Financings In Brief

Alma Lasers going public: Maker of non-invasive, energy-based aesthetic treatment devices plans an initial public stock offering worth up to $86.3 million. The proceeds are tabbed primarily for debt repayment, as well as "for general corporate purposes, including for strategic acquisitions," Alma says. The Israel-based firm reported sales of $62 million for the first nine months of 2007 - roughly the same as for all of 2006 - with a 30% operating profit margin. Competitors in the crowded $1.1 billion global market for energy-based aesthetic treatment devices also include Aesthera, Candela, Cutera, Cynosure, Lumenis, Palomar, Radiancy, Reliant, Sciton, Syneron, Thermage and Ultrashape. The market is projected to grow at a compound annual rate of 10%, reaching $1.8 billion in 2011, Alma notes in its Jan. 3 prospectus filed with the Securities and Exchange Commission. However, the stocks of most of Alma's publicly-traded competitors went down last year, due in part to concerns that an economic downturn could curb elective procedure volumes (1"The Gray Sheet" Jan. 21, 2008, p. 7). Underwriters for the proposed IPO include Citigroup Global Markets, UBS Investment Bank, William Blair & Company and Jefferies & Company

Related Content

Latest News
See All
UsernamePublicRestriction

Register

MT025675

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel